Evaluation of Hyperthyroidism and Hyperthyroid Goiter

  • Mirjam Christ-Crain
  • Nils G. Morgenthaler
  • Beat Müller


Thyroid Hormone Thyroid Gland Radioactive Iodine Multinodular Goiter Antithyroid Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Wartofsky L (2001) The thyroid gland. In: Becker KL (ed) Principles and practice of endocrinology and metabolism. Lippincott Williams & Wilkins, Philadelphia, pp 308–471Google Scholar
  2. 2.
    Spencer CA, et al (1990) Applications of a new chemiluminometric thyrotropin assay to subnormal measurement. J Clin Endocrinol Metab 70:453–460PubMedCrossRefGoogle Scholar
  3. 3.
    Christ-Crain M, et al (2002) Basal TSH levels compared with TRH-stimulated TSH levels to diagnose different degrees of TSH suppression: diagnostic and therapeutic impact of assay performance. Eur J Clin Invest 32:931–937PubMedCrossRefGoogle Scholar
  4. 4.
    Utiger RD (1995) Cigarette smoking and the thyroid. N Engl J Med 333:1001–1002PubMedCrossRefGoogle Scholar
  5. 5.
    Winsa B, et al (1991) Stressful life events and Graves’ disease. Lancet 338:1475–1479PubMedCrossRefGoogle Scholar
  6. 6.
    Weetman AP (2000) Graves’ disease. N Engl J Med 343:1236–1248PubMedCrossRefGoogle Scholar
  7. 7.
    Zulewski H, et al (1999) Evaluation of procollagen III peptide as a marker of tissue hyperthyroidism in long-term treated women with TSH suppressive doses of thyroxine. Exp Clin Endocrinol Diabetes 107:190–194PubMedGoogle Scholar
  8. 8.
    Bartley GB, et al (1996) Chronology of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmol 121:426–434PubMedGoogle Scholar
  9. 9.
    Kendall-Taylor P, et al (1998) Clinical presentation of thyroid associated orbitopathy. Thyroid 8:427–428PubMedCrossRefGoogle Scholar
  10. 10.
    Mourits MP, et al (1997) Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol (Oxf) 47:9–14CrossRefGoogle Scholar
  11. 11.
    Gerding MN, et al (2000) Assessment of disease activity in Graves’ ophthalmopathy by orbital ultrasonography and clinical parameters. Clin Endocrinol (Oxf) 52:641–646CrossRefGoogle Scholar
  12. 12.
    Morgenthaler NG (1999) New assay systems for thyrotropin receptor antibodies. Curr Opin Endocrinol Diabetes 6:251–260CrossRefGoogle Scholar
  13. 13.
    Schott M, et al (2005) TSH-receptor autoantibodies in Graves’ disease: recent developments in the diagnosis and therapy monitoring. Trends Endocrinol Metab 16:243–248PubMedCrossRefGoogle Scholar
  14. 14.
    Singer PA, et al (1995) Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association. JAMA 273:808–812PubMedCrossRefGoogle Scholar
  15. 15.
    Cooper DS (1984) Antithyroid drugs. N Engl J Med 311:1353–1362PubMedCrossRefGoogle Scholar
  16. 16.
    Maugendre D, et al (1999) Antithyroid drugs and Graves’ disease: prospective randomized assessment of long-term treatment. Clin Endocrinol (Oxf) 50:127–132CrossRefGoogle Scholar
  17. 17.
    Schott M, et al (2004) Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves’ disease. Horm Metab Res 36:92–96PubMedCrossRefGoogle Scholar
  18. 18.
    Saenger EL, et al (1968) Incidence of leukemia following treatment of hyperthyroidism. Preliminary report of the Cooperative Thyrotoxicosis Therapy Follow-Up Study. JAMA 205:855–862PubMedCrossRefGoogle Scholar
  19. 19.
    Farrar JJ, et al (1991) Iodine-131 treatment of hyperthyroidism: current issues. Clin Endocrinol (Oxf) 35:207–212Google Scholar
  20. 20.
    Franklyn JA (1994) The management of hyperthyroidism. N Engl J Med 330:1731–1738PubMedCrossRefGoogle Scholar
  21. 21.
    Walter MA, et al (2004) Radioiodine therapy in hyperthyroidism: inverse correlation of pretherapeutic iodine uptake level and post-therapeutic outcome. Eur J Clin Invest 34:365–370PubMedCrossRefGoogle Scholar
  22. 22.
    Imseis RE, et al (1998) Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism. J Clin Endocrinol Metab 83:685–687PubMedCrossRefGoogle Scholar
  23. 23.
    Walter MA, et al (2005) Paired comparison of radioiodine uptakes and thyroid hormone levels on/off simultaneous carbimazole medication. A prospective paired comparison. Nuklearmedizin 44:33–36PubMedGoogle Scholar
  24. 24.
    Bartalena L, et al (1998) Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med 338:73–78PubMedCrossRefGoogle Scholar
  25. 25.
    Bartalena L, et al (1997) Treating severe Graves’ ophthalmopathy. Baillieres Clin Endocrinol Metab 11:521–536PubMedCrossRefGoogle Scholar
  26. 26.
    Garrity JA, et al (1993) Results of transantral orbital decompression in 428 patients with severe Graves’ ophthalmopathy. Am J Ophthalmol 116:533–547PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2007

Authors and Affiliations

  • Mirjam Christ-Crain
    • 1
  • Nils G. Morgenthaler
    • 2
  • Beat Müller
    • 3
  1. 1.Department of Endocrinology, John Vane Science CentreBarts and the London Medical SchoolLondonUK
  2. 2.Institut für Experimentelle Endokrinologie, Charité Campus MitteUniversitätsmedizin BerlinBerlinGermany
  3. 3.Dept. of Endocrinology, Diabetology and Clinical NutritionUniversity HospitalBaselSwitzerland

Personalised recommendations